Stanley Fahn Lecture 2005:: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

被引:431
作者
Braak, Heiko
Bohl, Juergen R.
Muller, Christian M.
Rub, Udo
de Vos, Rob A. I.
Del Tredici, Kelly
机构
[1] Goethe Univ Frankfurt, Inst Clin Neuroanat, D-60590 Frankfurt, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Neuropathol, D-6500 Mainz, Germany
[3] Lab Pathol Oost Nederland, Enschede, Netherlands
关键词
aging; alpha-synuclein; Lewy bodies/neurites; pathoarchitectonics; sporadic Parkinson's disease; staging;
D O I
10.1002/mds.21065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The synucleinopathy known as sporadic Parkinson's disease (PD) is a multisystem disorder that severely damages predisposed nerve cell types in circumscribed regions of the human nervous system. A recent staging procedure for the inclusion body pathology associated with PD proposes that, in the brain, the pathological process (formation of proteinaceous intraneuronal Lewy bodies and Lewy neurites) begins at two sites and continues in a topographically predictable sequence in six stages, during which components of the olfactory, autonomic, limbic, and somatomotor systems become progressively involved. In stages 1 to 2, the Lewy body pathology is confined to the medulla oblongata/pontine tegmentum and anterior olfactory structures. In stages 3 to 4, the substantia nigra and other nuclei of the basal mid- and forebrain become the focus of initially subtle and, then, severe changes. During this phase, the illness probably becomes clinically manifest. In the final stages 5 to 6, the lesions appear in the neocortex. This cross-sectional study originally was performed on 168 autopsy cases using material from 69 incidental cases and 41 clinically diagnosed PD patients as well as 58 age- and gender-matched controls. Here, the staging hypothesis is critically reconsidered and discussed. (C) 2006 Movement Disorder Society.
引用
收藏
页码:2042 / 2051
页数:10
相关论文
共 111 条
  • [1] Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?
    Aarsland, D
    Ballard, CG
    Halliday, G
    [J]. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2004, 17 (03) : 137 - 145
  • [2] Frequency of bowel movements and the future risk of Parkinson's disease
    Abbott, RD
    Petrovitch, H
    White, LR
    Masaki, KH
    Tanner, CM
    Curb, JD
    Grandinetti, A
    Blanchette, PL
    Popper, JS
    Ross, GW
    [J]. NEUROLOGY, 2001, 57 (03) : 456 - 462
  • [3] Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease
    Ahlskog, JE
    [J]. MOVEMENT DISORDERS, 2005, 20 (03) : 271 - 282
  • [4] [Anonymous], 2003, NEURODEGENERATION MO
  • [5] Parkinson disease neuropathology - Later-developing dementia and loss of the levodopa response
    Apaydin, H
    Ahlskog, JE
    Parisi, JE
    Boeve, BF
    Dickson, DW
    [J]. ARCHIVES OF NEUROLOGY, 2002, 59 (01) : 102 - 112
  • [6] AGING, ENERGY, AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES
    BEAL, MF
    [J]. ANNALS OF NEUROLOGY, 1995, 38 (03) : 357 - 366
  • [7] Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell
    Berendse, HW
    Booij, J
    Francot, CMJE
    Bergmans, PLM
    Hijman, R
    Stoof, JC
    Wolters, EC
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (01) : 34 - 41
  • [8] Bohus B, 1996, PROG BRAIN RES, V107, P447
  • [9] Braak H, 1998, PROG BRAIN RES, V117, P267
  • [10] Stages in the development of Parkinson's disease-related pathology
    Braak, H
    Ghebremedhin, E
    Rüb, U
    Bratzke, H
    Del Tredici, K
    [J]. CELL AND TISSUE RESEARCH, 2004, 318 (01) : 121 - 134